Investing.com - 2Seventy Bio reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
2Seventy Bio announced earnings per share of $-1.76 on revenue of $13.41M. Analysts polled by Investing.com anticipated EPS of $-1.69 on revenue of $12.46M.
2Seventy Bio shares are down 5.02% from the beginning of the year , still down 65.74% from its 52 week high of $44.34 set on Tuesday, November 9, 2021.
2Seventy Bio follows other major Healthcare sector earnings this month
2Seventy Bio's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar